# Safety, Tolerability and Pharmacokinetic Study of MRG-201 in Healthy Volunteers

> **NCT02603224** · PHASE1 · COMPLETED · sponsor: **miRagen Therapeutics, Inc.** · enrollment: 54 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** MRG-201
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02603224
- **Lead sponsor:** miRagen Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2017-04
- **Final completion:** 2017-04
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2017-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02603224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02603224, "Safety, Tolerability and Pharmacokinetic Study of MRG-201 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02603224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*